HTG Molecular Diagnostics: KOL Webinar on Drug Candidate Attrition – How to Improve Clinical Development Success and Patient Outcomes
About The Event
The webinar will feature a presentation from Key Opinion Leader Robert Spitale, PhD (University of California, Irvine) who will discuss the use of RNA-based platform technologies in drug discovery.
The HTG Therapeutics team will introduce their proprietary transcriptome-informed drug discovery platform as the cornerstone of their differentiated approach to small molecule drug discovery. They will also discuss how their therapeutically-agnostic approach can be applied to render increasingly derisked small molecule early development drug candidates and a better understanding of diseases and treatment options for patients.
HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, clinical diagnostics, and targeted therapeutics across a variety of disease areas.
A live question and answer session will follow.